BTIG Upgrades Doximity (DOCS) Stock to Buy from Neutral

On June 2, BTIG analysts upgraded Doximity, Inc. (NYSE:DOCS)’s stock from “Neutral” to “Buy” with the price objective of $80. The analysts exhibited confidence in Doximity, Inc. (NYSE:DOCS)’s potential, mentioning the increasing demand for high-quality SaaS solutions in the bio-pharma industry amidst the macroeconomic uncertainties.

A pathologist and a laboratory assistant in a laboratory researching medical news and data.

As per the analysts, while there are some ongoing challenges, including potential tariffs and drug pricing reforms, the demand for precise SaaS commercialization efforts is projected to increase.

The analysts opine that Doximity, Inc. (NYSE:DOCS)’s recent financial guidance is conservative. For Q1 2026, the company expects revenue in the range of $139 million – $140 million and adjusted EBITDA of between $71 million – $72 million. For FY 2026, it expects revenue of between $619 million – $631 million, and adjusted EBITDA in the range of $333 million – $345 million.

In Q4 2025, the company’s FCF came in at $97.0 million as compared to $62.3 million, reflecting a rise of 56% YoY. The self-service portal, which provides increased return on investment for clients, was also regarded as a positive factor for Doximity, Inc. (NYSE:DOCS)’s growth prospects.

While we acknowledge the potential of DOCS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than DOCS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.